查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553705

急性淋巴性白血病治療市場規模、佔有率和趨勢分析報告：按產品、化療、應用、年齡層、性別、最終用途、地區和細分趨勢：2024-2030

Acute Lymphocytic Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Product, By Chemotherapy, By Application, By Age Group, By Gender, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

急性淋巴性白血病治療市場成長與趨勢

Grand View Research, Inc.的最新報告顯示，到2030年，全球急性淋巴性白血病治療市場規模預計將達到49.9億美元。

預計2024年至2030年該市場將以7.0%的複合年成長率成長。急性淋巴性白血病 (ALL) 診斷的公共和私人舉措的增加、骨髓切片檢查數量的增加以及其他治療方案的可用性預計將增加 ALL 治療的採用率。例如，聯合國兒童基金會（英國）的嬰兒友善計劃計劃和加拿大醫院與醫療保健提供者之間的合作方式 SickKids-Caribbean Initiative 為符合某些合格標準的患有 ALL 的嬰幼兒提供免費診斷。服務。

此外，ALL 發生率的上升預計將提振市場。此病多發於5歲以下兒童。 0 至 20 歲之間患 ALL 的風險最高。然而，成年人也有罹患這種疾病的風險。被診斷出患有這種疾病的男性平均年齡約為 55 歲。

急性淋巴性白血病治療市場報告亮點

  • 2023 年，化療佔最大的市場收益佔有率，達到 39.9%。化療已在治療 ALL 方面取得了成功，並實現了高緩解率和長期存活率。
  • 2023年，前驅B細胞急性淋巴性白血病細分市場佔40.4%的市場佔有率。近年來，隨著診斷技術的進步，使該疾病的識別變得更加容易，前體 B 細胞急性淋巴性白血病(ALL) 的發生率一直在上升。
  • 2023年，兒科（0-18歲）細分市場佔63.9%的市場佔有率。急性淋巴性白血病是兒童最常見的癌症，約佔所有兒童癌症的 25%。
  • 到 2023 年，男性細分市場將佔據 57.1%的市場佔有率，而女性細分市場預計在預測期內複合年成長率為 6.7%。
  • 2023年北美急性淋巴性白血病治療佔主導地位，佔有率為37.6%。美國的急性淋巴性白血病治療在北美市場佔據主導地位，2023年佔有率為89.3%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章急性淋巴性白血病治療市場變數、趨勢、範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 急性淋巴性白血病治療市場分析工具
    • 波特的分析
    • PESTEL分析

第4章急性淋巴性白血病治療市場：依產品估計與趨勢分析

  • 細分儀表板
  • 急性淋巴性白血病治療市場：2023 年和 2030 年產品變化分析
  • 化療
  • 標靶治療
  • 放射治療
  • 幹細胞移植

第5章急性淋巴性白血病治療市場：按應用、估計和趨勢分析

  • 細分儀表板
  • 急性淋巴性白血病治療市場：2023 年和 2030 年應用變化分析
  • 費城染色體
  • 前體B細胞ALL
  • T細胞ALL

第6章急性淋巴性白血病治療市場：依年齡層別估計及趨勢分析

  • 細分儀表板
  • 急性淋巴性白血病治療市場：2023 年和 2030 年年齡層變化分析
  • 嬰兒（0-18歲）
  • 成人（19歲以上）

第7章急性淋巴性白血病治療市場：性別、估計與趨勢分析

  • 細分儀表板
  • 急性淋巴性白血病治療市場：性別差異分析，2023 年和 2030 年
  • 男性
  • 女士

第8章急性淋巴性白血病治療市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 急性淋巴性白血病治療市場：2023 年和 2030 年最終用途變化分析
  • 醫院/診所
  • 癌症護理中心
  • 研究/學術機構

第 9 章急性淋巴性白血病治療市場：區域、估計和趨勢分析

  • 2023年及2030年急性淋巴性白血病治療市場佔有率（按地區），百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Bristol-Myer Squibb Company
    • Celegene Corporation
    • Eisai Co., Ltd.
    • Erytech Pharma
    • F. Hoffmann-La Roche Ltd
    • Genmab A/S
    • GSK plc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
簡介目錄
Product Code: GVR-1-68038-645-5

Acute Lymphocytic Leukemia Therapeutics Market Growth & Trends:

The global acute lymphocytic leukemia therapeutics market size is anticipated to reach USD 4.99 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 7.0% from 2024 to 2030. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Acute Lymphocytic Leukemia Therapeutics Market Report Highlights:

  • Chemotherapy accounted for the largest market revenue share of 39.9% in 2023. Chemotherapy has shown success in the treatment of ALL by achieving high rates of remission and long-term survival.
  • The precursor B-cell acute lymphocytic leukemia segment accounted for the market share of 40.4% in 2023. The incidence of precursor B-cell ALL has been increasing in recent years due to several factors such as improvements in diagnostic techniques, which have led to better identification of the disease.
  • The children (0-18) segment accounted for the market share of 63.9% in 2023. Acute lymphocytic leukemia is the most common type of cancer in children, accounting for about 25% of all childhood cancers.
  • The male segment accounted for the market share of 57.1% in 2023 and the female segment is expected to register a CAGR of 6.7% during the forecast period.
  • North America acute lymphocytic leukemia therapeutics held a dominant position with a share of 37.6% in 2023. The U.S. acute lymphocytic leukemia therapeutics dominated the North America market with a share of 89.3% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Acute Lymphocytic Leukemia Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Acute Lymphocytic Leukemia Therapeutics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Acute Lymphocytic Leukemia Therapeutics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Acute Lymphocytic Leukemia Therapeutics Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1. Hyper-CVAD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. CALGB 8811 Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Linker Regimen Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.4. Nucleoside Metabolic Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.5. Oncaspar Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Radiation Therapy
    • 4.5.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Stem Cell Transplantation
    • 4.6.1. Stem Cell Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Acute Lymphocytic Leukemia Therapeutics Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Acute Lymphocytic Leukemia Therapeutics Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Philadelphia Chromosome
    • 5.3.1. Philadelphia Chromosome Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Precursor B-cell ALL
    • 5.4.1. Precursor B-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. T-cell ALL
    • 5.5.1. T-cell ALL Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Acute Lymphocytic Leukemia Therapeutics Market: Age Group Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Children (0-18)
    • 6.3.1. Children (0-18) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Adults (19 +)
    • 6.4.1. Adults (19 +) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Acute Lymphocytic Leukemia Therapeutics Market: Gender Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Acute Lymphocytic Leukemia Therapeutics Market: Gender Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Male
    • 7.3.1. Male Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Female
    • 7.4.1. Female Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Acute Lymphocytic Leukemia Therapeutics Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Acute Lymphocytic Leukemia Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 8.3. Hospitals & Clinics
    • 8.3.1. Hospitals & clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Cancer Care Centers
    • 8.4.1. Cancer Care Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Research and academic institutes
    • 8.5.1. Research and Academic Institutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Acute Lymphocytic Leukemia Therapeutics Market: Regional Estimates & Trend Analysis

  • 9.1. Acute Lymphocytic Leukemia Therapeutics Market Share, By Region, 2023 & 2030, USD Million
  • 9.2. North America
    • 9.2.1. North America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. U.S. Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Canada Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.2.4. Mexico
      • 9.2.4.1. Mexico Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. UK Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Germany Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. France Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Italy Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Spain Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Denmark Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Sweden Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Norway Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. China
      • 9.4.2.1. China Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Japan
      • 9.4.3.1. Japan Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. India Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.5. South Korea
      • 9.4.5.1. South Korea Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.6. Australia
      • 9.4.6.1. Australia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.7. Thailand
      • 9.4.7.1. Thailand Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Brazil Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Argentina
      • 9.5.3.1. Argentina Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. South Africa Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Saudi Arabia Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. UAE Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Kuwait Acute Lymphocytic Leukemia Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis by Key Market Participants
  • 10.2. Company Categorization
  • 10.3. Company Heat Map Analysis
  • 10.4. Company Profiles
    • 10.4.1. Bristol-Myer Squibb Company
      • 10.4.1.1. Participant's Overview
      • 10.4.1.2. Financial Performance
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Recent Developments/ Strategic Initiatives
    • 10.4.2. Celegene Corporation
      • 10.4.2.1. Participant's Overview
      • 10.4.2.2. Financial Performance
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Recent Developments/ Strategic Initiatives
    • 10.4.3. Eisai Co., Ltd.
      • 10.4.3.1. Participant's Overview
      • 10.4.3.2. Financial Performance
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Recent Developments/ Strategic Initiatives
    • 10.4.4. Erytech Pharma
      • 10.4.4.1. Participant's Overview
      • 10.4.4.2. Financial Performance
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Recent Developments/ Strategic Initiatives
    • 10.4.5. F. Hoffmann-La Roche Ltd
      • 10.4.5.1. Participant's Overview
      • 10.4.5.2. Financial Performance
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Recent Developments/ Strategic Initiatives
    • 10.4.6. Genmab A/S
      • 10.4.6.1. Participant's Overview
      • 10.4.6.2. Financial Performance
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Recent Developments/ Strategic Initiatives
    • 10.4.7. GSK plc.
      • 10.4.7.1. Participant's Overview
      • 10.4.7.2. Financial Performance
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Recent Developments/ Strategic Initiatives
    • 10.4.8. Novartis AG
      • 10.4.8.1. Participant's Overview
      • 10.4.8.2. Financial Performance
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Recent Developments/ Strategic Initiatives
    • 10.4.9. Pfizer Inc.
      • 10.4.9.1. Participant's Overview
      • 10.4.9.2. Financial Performance
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Recent Developments/ Strategic Initiatives
    • 10.4.10. Sanofi
      • 10.4.10.1. Participant's Overview
      • 10.4.10.2. Financial Performance
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Recent Developments/ Strategic Initiatives